FōLIUS LABS

Folius Labs is a biotechnology company focused on the discovery and development of novel small molecule therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages deep expertise in ion channel pharmacology, specifically targeting the Transient Receptor Potential (TRP) channel family. Their lead program, FL-001, is a selective TRPC4/5 inhibitor designed to treat Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD) through a unique mechanism of action. By modulating these channels, Folius Labs aims to provide rapid-acting and more effective treatment options for patients suffering from stress-related mental health conditions. The company is headquartered in Chicago and operates within the regional life sciences ecosystem.